WO2013068557A1 - Cellules souches pouvant être infectées par des virus - Google Patents

Cellules souches pouvant être infectées par des virus Download PDF

Info

Publication number
WO2013068557A1
WO2013068557A1 PCT/EP2012/072316 EP2012072316W WO2013068557A1 WO 2013068557 A1 WO2013068557 A1 WO 2013068557A1 EP 2012072316 W EP2012072316 W EP 2012072316W WO 2013068557 A1 WO2013068557 A1 WO 2013068557A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
virus
hepatotropic
hepatitis
days
Prior art date
Application number
PCT/EP2012/072316
Other languages
English (en)
Inventor
Frederik NEVENS
Johan Neyts
Jan Paeshuyse
Philip ROELANDT
Cathérine VERFAILLIE
Original Assignee
Katholieke Universiteit Leuven
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katholieke Universiteit Leuven filed Critical Katholieke Universiteit Leuven
Publication of WO2013068557A1 publication Critical patent/WO2013068557A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/12—Hepatocyte growth factor [HGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24251—Methods of production or purification of viral material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G01N2333/186—Hepatitis C; Hepatitis NANB
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Definitions

  • the invention is directed to methods for culturing cells so that the cells are induced to differentiate into cells that express a hepatocyte phenotype and/or hepatocyte progenitor phenotype which support complete replication of hepatitis viruses and other hepatotropic pathogens, more particularly hepatitis C virus (HCV). More particularly, the invention relates to methods for culturing cells so that the cells are induced to differentiate into cells that express a definitive endodermal phenotype, a liver-committed endodermal phenotype, a hepatoblast phenotype, and hepatocyte phenotype which can be infected with and support the complete replication of hepatitis viruses, more particularly hepatitis C virus.
  • HCV hepatitis C virus
  • the invention relates to the development of a tool suitable for the search, discovery and validation of inhibitors of HCV replication and of other hepatotropic pathogens, more particularly HCV antiviral drugs and therapies.
  • the invention further relates to methods for inducing hepatotropic virus, replication in vitro, and more particularly to a simple in vitro replication assay of hepatotropic viruses which enables productive and sustained infectious hepatotropic virus production, eg. for the hepatotropic virus HCV.
  • the cells produced by the methods of the invention are thus useful, among other things, for toxicity studies and screening for treatments/drugs against hepatitis viruses, more particularly hepatitis C virus.
  • iPSC induced pluripotent stem cells
  • hepatocytes derived from stem cells more particularly human embryonic stem cells (hESC) (H9 and HI cells) or hiPSC, can support the complete HCV replication cycle including the production of infectious virus.
  • hESC human embryonic stem cells
  • hiPSC human embryonic stem cells
  • the invention is based on methods developed by the inventors to produce a renewable source of hepatocytes in vitro, which is infectable with hepatitis virus and supports the complete replication of hepatitis viruses, more particularly HCV.
  • Said renewable source of hepatocytes, the method of the present invention and the screening assays disclosed herein, are useful for the screening and development of compounds, drugs and therapies for diseases caused by hepatotropic pathogens, such as viral hepatotropic pathogens, more particularly Hepatitis viruses such as HAV and HCV; and Flaviviruses such as Dengue Fever Virus and Yellow Fever Virus.
  • WO2009013254 also discloses methods for inducing human blastocysts stem cells to differentiate into hepatocyte-like cell progenitor cells. Said prior art methods, however, have the disadvantage that multiple expensive growth factors are used in each step of the differentiation protocol. Furthermore, none of said prior art documents actually discloses the infection of the obtained cells with hepatotropic pathogens.
  • the present invention aimed at further optimizing specific cell culture conditions to successfully produce cells that express phenotypes of hepatocytes which were subsequently successfully infected with hepatotropic pathogens, and which furthermore were able to support the complete replication of hepatotropic viruses.
  • the newly optimized culture method according to the present invention is in particular interesting in that the cells can be grown FBS-free and in the presence of less growth factors.
  • a method for inducing stem cells to differentiate into hepatocyte cells or cells with a hepatocyte phenotype comprising the steps of:
  • step (b) then culturing the cells of step (a) in BMP4 containing medium
  • step (c) then culturing the cells of step (b) in FGF1 containing medium;
  • step (d) then culturing the cells of step (c) in HGF containing medium;
  • steps (a), (b) or (c) wherein at least in one of steps (a), (b) or (c) only a single growth factor is used.
  • the ActivinA concentration in the medium is from about 10 ng/ml to about 1000 ng/ml; in particular about 100 ng/ml;
  • the BMP4 concentration in the medium is from about 5 ng/ml to about 500 ng/ml; in particular about 50 ng/ml;
  • the FGF1 concentration in the medium is from about 5 ng/ml to about 500 ng/ml; in particular about 50 ng/ml; and in step (d) the HGF concentration in the medium is from about 2 ng/ml to about 200 ng/ml; in particular about 20 ng/ml.
  • step (a) further comprises Wnt3a.
  • step (b) about four to seven days in step (b), in particular about four days;
  • step (c) about four to seven days in step (c), in particular about four days and
  • step (d) about four to thirty days in step (d), in particular about sixteen days.
  • step (a) comprises culturing the cells for about two days in ActivinA- and Wnt3a-containing medium followed by culturing for about two days in ActivinA containing medium.
  • step (b) then culturing the cells of step (a) with 50 ng/ml BMP4 for 4 days;
  • step (c) then culturing the cells of step (b) with 50 ng/ml FGF1 for 4 days;
  • step (d) then culturing the cells of step (c) with 20 ng/ml HGF for 16 days.
  • the cells are cultured in the absence of serum.
  • the stem cells are Embyronic Stem Cells (ESC) or induced Pluripotent Stem Cells (iPSC).
  • stem cell derived hepatocytes obtainable by the method according to anyone of statements 1-12 as an in vitro culturing system of hepatotropic pathogen.
  • hepatotropic pathogen is a hepatotropic virus. 15. Use according to anyone of statements 12 and 13 for the screening and development of compounds, drugs and therapies for hepatotropic pathogens.
  • virus entry comprising (-) and (+) strand synthesis, viral protein synthesis, virus assembly, virus trafficking, or virus release.
  • hepatotropic virus is selected from: Yellow Fever Virus, Dengue Fever Virus, Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E, and Hepatitis G virus; in particular hepatitis C.
  • a screening assay for agents which possesses anti-viral activity comprising:
  • a screening assay for agents which possesses anti-hepatotropic pathogen activity comprising:
  • a screening assay for agents which possesses anti-hepatotropic pathogen activity comprising:
  • step (b) culturing the cells obtained in step (a) in the presence of a hepatotropic pathogen and said agent;
  • a screening assay for agents which possesses anti -hepatitis activity comprising:
  • step (b) culturing the cells obtained in step (a) in the presence of a hepatitis virus and said agent;
  • a method for identifying an agent with anti-hepatotropic pathogen activity comprising:
  • test compound inhibits the biological activity of said hepatotropic pathogen; wherein a test agent which inhibits said biological activity is a compound with said inhibitory effect.
  • An in vitro culture system for a hepatotropic virus which enables the screening and development of compounds, drugs and therapies for hepatotropic viral diseases, comprising:
  • step (b) then culturing the cells of step (a) in BMP4 containing medium;
  • step (c) then culturing the cells of step (b) in FGF1 containing medium;
  • step (d) then culturing the cells of step (c) in HGF containing medium.
  • hepatotropic virus is selected from: Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E, Hepatitis F, and Hepatitis G virus.
  • step (a) the ActivinA concentration in the medium is about 100 ng/ml; in step (b) the BMP4 concentration in the medium is about 50 ng/ml; in step (c) the FGF1 concentration in the medium is about 50 ng/ml; and in step (d) the HGF concentration in the medium is about 20 ng/ml.
  • step (a) comprises culturing the cells for about two days in ActivinA- and Wnt3a-containing medium followed by culturing for about two days in ActivinA containing medium.
  • step (a) comprises culturing the cells for about two days in ActivinA- and Wnt3a-containing medium followed by culturing for about two days in ActivinA containing medium.
  • step (a) then culturing the cells of step (a) with 50 ng/ml BMP4 for 4 days;
  • step (b) then culturing the cells of step (b) with 50 ng/ml FGF1 for 4 days;
  • step (c) then culturing the cells of step (c) with 20 ng/ml HGF for 16 days.
  • a screening assay comprising a measurable biological activity of a hepatotropic virus in an in vitro culture system of the present invention
  • test compound inhibits the biological activity of said hepatotropic virus; wherein a test compound which inhibits said biological activity is a compound with said inhibitory effect.
  • a compound having therapeutic effect on a hepatotropic virus comprising:
  • test compound inhibits the biological activity of said hepatotropic virus; wherein a test compound which inhibits said biological activity is a compound with said inhibitory or therapeutic effect.
  • compositions for the treatment of a hepatotropic infection wherein said composition comprises the compound of statement 27 to 49.
  • Any stem cell can be used in the embodiments of this invention as long as it can be differentiated towards a hepatocyte cell or a cell with a hepatocyte phenotype.
  • Particular differentiation protocols and methods for differentiation of such stem cells are well known to a person skilled in the art and are described for example in WO2010049752.
  • the stem cells are embryonic stem cells, more particularly, established embryonic stem cell lines may be used as ESC in the present invention.
  • the stem cells are iPSC.
  • the invention provides a method for inducing stem cells to differentiate into hepatocyte cells or cells with a hepatocyte phenotype (i.e. in vitro culture system), infectable with a hepatotropic pathogen. It further provides a screening assay for identification and testing compounds, drugs and therapies for their therapeutic effect on the disease caused by said hepatotropic pathogen.
  • the invention is, next to a screening tool or assay, also directed to methods of using the differentiated stem cells for studies of liver toxicity, for example, to identify or assess the toxicity of specific compounds.
  • the invention provides the means to assess for sensitivity or resistance of a particular hepatotropic pathogen, to a known antiviral compound or candidate antiviral compound.
  • such assessment enables an adaptation of the therapeutic regimen to better suit the sensitivity profile of the particular hepatotropic pathogen.
  • the hepatotropic pathogen is a viral hepatotropic pathogen or a hepatotropic virus such as a hepatitis virus or a flavivirus.
  • the hepatotropic pathogen is a non-viral or other hepatotropic pathogen such as a parasitic pathogen, such as for example Plasmodium.
  • the hepatotropic virus is a flavivirus such as Dengue Fever virus or Yellow Fever Virus; or a hepatitis virus such as hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E, hepatitis F, or hepatitis G virus (also known as GB virus C).
  • the hepatotropic virus is hepatitis C virus (HCV).
  • hepatitis is hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E, hepatitis F, or hepatitis G.
  • said hepatitis is hepatitis C.
  • Figure 2 Replication and egress of HCV.
  • FIG. 1 Inhibition of HCV Replication.
  • Figure 5. (A) Levels of HAV RNA in culture supernatant of stem cell-derived hepatocytes in culture supernatant at different days post infection and (B) intracellularly at day 31 post infection.
  • a or "an” means one or more than one.
  • composition comprising x and y
  • a method comprising the step of x encompasses any method in which x is carried out, whether x is the only step in the method or it is only one of the steps, no matter how many other steps there may be and no matter how simple or complex x is in comparison to them.
  • “Comprised of and similar phrases using words of the root "comprise” are used herein as synonyms of "comprising” and have the same meaning.
  • Effective amount generally means an amount which provides the desired local or systemic effect.
  • an effective amount is an amount sufficient to effectuate a beneficial or desired clinical result.
  • the effective amounts can be provided all at once in a single administration or in fractional amounts that provide the effective amount in several administrations. The precise determination of what would be considered an effective amount may be based on factors individual to each subject, including their size, age, injury, and/or disease or injury being treated, and amount of time since the injury occurred or the disease began. One skilled in the art will be able to determine the effective amount for a given subject based on these considerations which are routine in the art.
  • effective dose means the same as "effective amount.”
  • EC cells were discovered from analysis of a type of cancer called a teratocarcinoma. In 1964, researchers noted that a single cell in teratocarcinomas could be isolated and remain undifferentiated in culture. This type of stem cell became known as an embryonic carcinoma cell (EC cell).
  • Embryonic Stem Cells are well known in the art and have been prepared from many different mammalian species for many years. Embryonic stem cells are stem cells derived from the inner cell mass of an early stage embryo known as a blastocyst. They are able to differentiate into all derivatives of the three primary germ layers: ectoderm, endoderm, and mesoderm. These include each of the more than 220 cell types in the adult body. The ES cells can become any tissue in the body, excluding placenta. Only the morula's cells are totipotent, able to become all tissues and a placenta. hESC are embryonic stem cells of human origing and several established hESC cell lines exist such as the ESC cell lines hESC-H9 and hESC- Hl .
  • Hepatic differentiation factors are chemical or biological factors that induce differentiation of stem and progenitor cells into more differentiated cells of the hepatic lineage. Hepatic differentiation factors include, but are not limited to, Wnt3a, Activin-A, FGF2, BMP4, FGF1, FGF4, FGF8b, HGF and Follistatin.
  • the initial cell may express Oct3/4.
  • Hepatocytes are cells with a hepathic phenotype.
  • Hepatocyte phenotype is a particular phenotype of cells that express albumin and keratin 18 (K T18) but not alpha fetoprotein (AFP) and keratin 19 (K T19); in addition, hepatocytes may express one or more of ALB, TAT, MRP2, G6P, PEPCK1, AAT, CX32, NTCP, OATP1B1, F5, F7, F9, VKORC1, CYP7A1 and CYP3A4.
  • Hepatotropic pathogens include two groups of pathogens:
  • - viral pathogens or hepatotropic viruses such as, but not limited to, hepatitis A, B, C, D, E, F and G virus; human cytomegalovirus (HCMV); Epstein-Barr virus (EBV); herpes simplex virus 1 & 2 (HSV-1 & HSV-2); varicella zoster virus (VZV); human herpesvirus type 6 (HHV6); measles virus; Rubella virus; enteroviruses; yellow fever virus; dengue fever virus; Crimean Congo hemorrhagic fever virus; Arenaviruses, including but not limited to, Junin virus (causing Argentinian hemorrhagic fever), Machupo virus (causing Venezuelan hemorrhagic fever), Lassa virus (causing Lassa fever); Rift Valley fever virus; Ebola virus and Marburg virus; and - parasitic pathogens such as, but not limited to, Plasmodium; Echinococcosis;
  • Fascioliasis Amebic liver disease causing pathogens such as, but not limited to, Entamoeba histolytica; Fungal abscess causing pathogens such as, but not limited to, the Candida species; Pyogenic liver abscess causing pathogens or bacteria such as, but not limited to, Streptococcus, E. coli, Klebsiella, Proteus, and Staphylococcus.
  • a hepatotropic infection is an infection with a hepatotropic pathogen.
  • Human stem cell or “hSC” is a stem cell as defined in this specification, from human origin. This includes human Embryonic Stem Cells and human Induced pluripotent stem cells.
  • IPC Intrapuripotent stem cells
  • IPS cells are somatic cells that have been reprogrammed. for example, by introducing exogenous genes that confer on the somatic cell a less differentiated phenotype. These cells can then be induced to differentiate into less differentiated progeny.
  • IPS cells have been derived using modifications of an approach originally discovered in 2006 (Yamanaka, S. et al, Cell Stem Cell, 1 :39-49 (2007)). For example, in one instance, to create IPS cells, scientists started with skin cells that were then modified by a standard laboratory technique using retroviruses to insert genes into the cellular DNA.
  • the inserted genes were Oct4, Sox2, Lif4, and c-myc, known to act together as natural regulators to keep cells in an embryonic stem cell-like state. These cells have been described in the literature. See, for example, Wernig et al, PNAS, 105:5856- 5861 (2008); Jaenisch et al, Cell, 132:567-582 (2008); Hanna et al, Cell, 133:250-264 (2008); and Brambrink et al, Cell Stem Cell, 2: 151-159 (2008). These references are incorporated by reference for teaching IPSCs and methods for producing them. It is also possible that such cells can be created by specific culture conditions (exposure to specific agents).
  • isolated refers to a cell or cells that are not associated with one or more cells or one or more cellular components that are associated with the cell or cells in vivo.
  • An "enriched population” means a relative increase in numbers of a desired cell relative to one or more other cell types in vivo or in primary culture.
  • isolated does not indicate the presence of only a specific desired cell, such as a stem or hepatic progenitor cell. Rather, the term “isolated” indicates that the cells are removed from their natural tissue environment and are present at a higher concentration as compared to the normal tissue environment. Accordingly, an "isolated” cell population may further include cell types in addition to stem cells and may include additional tissue components. This also can be expressed in terms of cell doublings, for examples.
  • a cell may have undergone 10, 20, 30, 40 or more doublings in vitro or ex vivo so that it is enriched compared to its original numbers in vivo or in its original tissue environment (e.g., bone marrow, peripheral blood, adipose tissue, etc.)
  • tissue environment e.g., bone marrow, peripheral blood, adipose tissue, etc.
  • MAPC multipotent adult progenitor cell
  • endoderm a non-embryonic stem cell that can give rise to cell lineages of all three germ layers (i.e., endoderm, mesoderm and ectoderm) upon differentiation.
  • human MAPCs express telomerase, Oct 3/4 (i.e., Oct 3A), rex-1, rox-1 and sox-2, and may express SSEA-4.
  • telomerase i.e., Oct 3A
  • rex-1 rex-1
  • rox-1 a non-embryonic somatic cell.
  • MAPCs constitutively express Oct 3/4 and high levels of telomerase (Jiang, Y. et al, Nature, 418:41 (2002); Exp Hematol, 30:896, 2002).
  • MAPCs derived from human, mouse, rat or other mammals appear to be the only normal, non-malignant, somatic cell (i.e., non-germ cell) known to date to express very high levels of telomerase even in late passage cells.
  • the telomeres are extended in MAPCs and they are karyotypically normal. Because MAPCs injected into a mammal can migrate to and assimilate within multiple organs, MAPCs are self-renewing stem cells.
  • Multipotent with respect to the term in “MAPC,” refers to the ability to give rise to cell lineages of more than one primitive germ layer (i.e., endoderm, mesoderm and ectoderm) upon differentiation, such as all three. This term is not used consistently in the literature.
  • Pluripotent as used herein means any cell that, when exposed to Wnt3a and Activin A at the specified amounts, gives rise to cells with a definitive endodermal phenotype. Such cells may have the ability to give rise to cell lineages of more than one primitive germ layer (i.e., endoderm, mesoderm and ectoderm) upon differentiation, such as all three. "Primordial embryonic germ cells” (PG or EG cells) can be cultured and stimulated to produce many less differentiated cell types.
  • PG primordial embryonic germ cells
  • Progenitor cells are cells produced during differentiation of a stem cell that have some, but not all, of the characteristics of their terminally-differentiated progeny.
  • progenitor as used in the acronym “MAPC” does not limit these cells to a particular lineage.
  • a hepatocyte progenitor is any cell in the hepatocyte lineage that is less differentiated than a hepatocyte.
  • Self-renewal refers to the ability to produce replicate daughter stem cells having differentiation potential that is identical to those from which they arose. A similar term used in this context is “proliferation.”
  • stem cell means a cell that can undergo self-renewal (i.e., progeny with the same differentiation potential) and also produce progeny cells that are more restricted in differentiation potential.
  • a stem cell would also encompass a more differentiated cell that has dedifferentiated, for example, by nuclear transfer, by fusions with a more primitive stem cell, by introduction of specific transcription factors, or by culture under specific conditions.
  • Dedifferentiation may also be caused by the administration of certain compounds or exposure to a physical environment in vitro or in vivo that would cause the dedifferentiation.
  • Stem cells also may be derived from abnormal tissue, such as a teratocarcinoma and some other sources such as embryoid bodies (although these can be considered embryonic stem cells in that they are derived from embryonic tissue, although not directly from the inner cell mass).
  • abnormal tissue such as a teratocarcinoma and some other sources such as embryoid bodies (although these can be considered embryonic stem cells in that they are derived from embryonic tissue, although not directly from the inner cell mass).
  • Subject means a vertebrate, such as a mammal, such as a human. Mammals include, but are not limited to, humans, dogs, cats, horses, cows and pigs.
  • therapeutically effective amount refers to the amount determined to produce any therapeutic response in a mammal.
  • effective amounts of the compounds, agents or drugs may prolong the survivability of the patient, and/or inhibit overt clinical symptoms.
  • Treatments that are therapeutically effective within the meaning of the term as used herein, include treatments that improve a subject's quality of life even if they do not improve the disease outcome per se.
  • Such therapeutically effective amounts are ascertained by one of ordinary skill in the art through routine application to subject populations such as in clinical and pre-clinical trials. Thus, to "treat” means to deliver such an amount.
  • Treating are used broadly in relation to the invention and each such term encompasses, among others, preventing, ameliorating, inhibiting, or curing a deficiency, dysfunction, disease, or other deleterious process, including those that interfere with and/or result from a therapy.
  • compound molecule
  • agent agent
  • molecule therefore denotes for example chemicals, macromolecules, cell or tissue extracts (from plants or animals) and the like.
  • Non-limiting examples of molecules include nucleic acid molecules including oligonucleotides (like antisense or aptamers) and small interfering RNAs, antigene therapeutics, peptides, antibodies, carbohydrates, small molecules, pharmaceutical agents, and/or cellular therapies.
  • the agents can be selected and screened by a variety of means including random screening, rational selection and by rational design using for example protein or ligand modeling methods such as computer modeling.
  • the terms "rationally selected” or “rationally designed” are meant to define compounds which have been chosen based on the configuration of interacting domains of the present invention. As will be understood by the person of ordinary skill, macromolecules having non-naturally occurring modifications are also within the scope of the term "molecule”.
  • peptidomimetics well known in the pharmaceutical industry and generally referred to as peptide analogs can be generated by modeling as mentioned above.
  • analogs or functional derivatives of the compounds of this invention which can be made by several methods as is known by a person skilled in the art, are also contemplated within the scope of this invention.
  • the molecules identified in accordance with the teachings of the present invention have a therapeutic value in diseases or conditions associated with hepatitis virus infection, more particularly, HCV infection.
  • the molecules identified in accordance with the teachings of the present invention find utility in the development of more efficient anti- hepatitis virus compounds, more particularly, anti-HCV compounds.
  • the designation "functional derivative” denotes, in the context of a functional derivative of a sequence whether a nucleic acid or amino acid sequence, a molecule that retains a biological activity (either functional or structural) that is substantially similar to that of the original sequence. Substantially similar means in terms of nucleic acid or amino acid sequence molecules, a molecule that has at least 50%, more preferably at least 70%>, yet more preferably 80%, still more preferably 90%, again more preferable 95% and most preferably at least 98% nucleic acid or amino acid sequence identity with said nucleic acid or amino acid sequence molecule.
  • This functional derivative or equivalent may be a natural derivative or may be prepared synthetically.
  • Such derivatives include amino acid sequences having substitutions, deletions, or additions of one or more amino acids, provided that the biological activity of the protein is conserved.
  • the substituting amino acid When relating to a protein sequence, the substituting amino acid generally has chemico-physical properties which are similar to that of the substituted amino acid. The similar chemico-physical properties include, similarities in charge, bulkiness, hydrophobicity, hydrophylicity and the like.
  • the term "functional derivatives" is intended to include fragments, segments, variants, analogs, homologues or chemical derivatives of the subject matter of the present invention.
  • the present invention relates to an assay to screen for drugs for the treatment and/or prevention of a hepatotropic infection, more particularly a HCV infection.
  • such assays can be designed using cells from patients infected with such a hepatotropic virus (eg. HCV) having a known genotype.
  • a method for identifying, from a library of compounds, a compound with therapeutic effect on a hepatotropic infection, more particularly a HCV infection comprising providing a screening assay comprising a measurable biological activity of such a hepatotropic viral protein or gene, such as a HCV protein or gene (e.g.
  • in vitro' or measuring infectivity, (viral release etc.), contacting the screening assay whether in vitro or “cellular” with a test compound; and detecting if the test compound modulates the biological activity of said protein or gene or the infectivity of the virus; wherein a test compound which modulates the biological activity or the infectivity is a compound with this therapeutic effect.
  • the screening assay according to the present invention is preferably an “in vitro” screening assay, but it can also be performed “in vivo” such as for example in a suitable mouse model.
  • biological activity refers to any detectable biological activity of hepatotropic viral gene or protein, such as a HCV gene or protein. This includes any physiological function attributable to said gene or protein.
  • the invention provides assays for screening candidate or test compounds which interact with hepatotropic genes or proteins, such as HCV genes or proteins.
  • an assay is a cell-based assay in which a cell activity producing a hepatotropic virus such as a HCV is contacted with a test compound and the ability of the test compound to modulate the infectivity of said hepatotropic virus at different steps in said hepatotropic virus complete life cycle, (e.g., attachment, entry into cells, replication, maturation etc).
  • this invention also includes secondary anti- hepatotropic virus screens, such as anti-HCV screens, which may involve purified factors of said hepatotropic virus.
  • Tertiary screens may involve the study of the identified modulators in animal models for hepatotropic virus infection, such as animal models for HCV infection. Accordingly, it is within the scope of this invention to further use an agent identified as described herein in an appropriate animal model.
  • an agent identified as described herein can be used in an animal model to determine the efficacy, toxicity, or side effects of treatment with such an agent.
  • the toxicity of any test compound, including the test compound described in this invention can be analyzed in the cells produced by the methods of this invention in the absence of any (hepatitis) viral infection.
  • test compounds of the present invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries (peptide libraries) and small molecule libraries of compounds. Methods and Compositions of the Invention
  • the invention relates to a method for inducing stem cells to differentiate into hepatocyte cells or cells with a hepatocyte phenotype (i.e. in vitro culture system), which is suitable for the full replication cycle of hepatotropic pathogens; in particular hepatotropic viruses, more particularly hepatitis C virus (HCV), HAV, Dengue Fever Virus and Yellow Fever virus.
  • hepatotropic viruses more particularly hepatitis C virus (HCV), HAV, Dengue Fever Virus and Yellow Fever virus.
  • HCV hepatitis C virus
  • HAV hepatitis C virus
  • Dengue Fever Virus Dengue Fever Virus
  • Yellow Fever virus Yellow Fever virus.
  • the methods of the invention induce cells in culture to progress through the appropriate stages of hepatic development, thus recapitulating hepatic development in vitro and, as a result, give rise to cells having functional hepatic properties (e.g., biochemical and anatomical characteristics of he
  • Culture methods of the invention comprise a sequential addition of hepatic differentiation factors (herein also referred to as growth factors) to cells, wherein there is:
  • Activin A is added at concentrations of about 10 ng/ml to about 1,000 ng/ml ActivinA, more particularly about 100 ng/ml ActivinA;
  • steps (a), (b), (c) and (d) only a single growth factor is used. More in particular, at least in one, two or three of steps (a), (b), and (c), only a single growth factor is used.
  • the culture is continued for at least four days. More particularly, the cells are cultured in the first step for about two days in ActicinA and Wnt3A containing medium and about two days in ActicinA containing medium; in the second step for about four days; in the third step for about four days; and in the fourth step for about six days. In one embodiment, cells are cultured with Wnt3a for about 2 days. At one or more steps, the cells are cultured in a medium containing a serum concentration from 0% to about 2%, more particularly about 0%. In one embodiment, cells are cultured in 0% serum throughout the complete differentiation protocol.
  • the cells are cultured in a medium containing about 10 "4 M to about 10 "7 M dexamethasone, more particularly about 10 "6 M dexamethasone. Additionally, at one or more steps, the cells are cultured in a medium containing about 0.1 mg/ml to about 50 mg/ml insulin, more particularly about 2.5 mg/ml insulin.
  • Culture medium at each successive step of the methods of the present invention is prepared to contain only the growth factor(s) described above, and cells are washed between each step to reduce the presence of previously added growth factor(s). Alternatively, reduced concentrations of the previously provided factor(s) in a previous step can remain in the culture medium of the next step.
  • the methods of the present invention contemplate the use of any Wnt3a, Activin-A, BMP4, FGF1, and HGF known in the art and having conserved function, and from all species (e.g., orthologs from human, mouse, rat, monkey, pig and the like).
  • the hepatic differentiation factors of the present invention are well known to those skilled in the art.
  • Suitable forms of Wnt3a, Activin-A, BMP4, FGF1, and HGF include, but are not limited to, isolated polypeptides, which are optionally recombinant, including whole proteins, partial proteins (e.g., domains) and peptide fragments. Fragments of a polypeptide preferably are those fragments that retain the distinct functional capability of the particular factor, which in the present invention generally relates to the ability to influence hepatic differentiation (the specific function of each factor is well known in the art). Such polypeptides also include, but are not limited to, fusion proteins and chimeric proteins. Short polypeptides can be synthesized chemically using well-established methods of peptide synthesis.
  • Cytokines may be replaced by small molecules that activate the same signal pathway, such as GSK3b inhibitor for Wnt3a; kinase activating molecules for the FGFs.
  • the culture methods of the present invention comprise a sequential addition of hepatic differentiation factors to cells.
  • the hepatic differentiation factors Wnt3a and Activin A are added to the cells.
  • the concentration of Wnt3a that is added to the cells can range from about 5 ng/ml to about 500 ng/ml. However, the invention also encompasses sub-ranges of concentrations of Wnt3a. For example, from about 5-25 ng/ml, 25-50 ng/ml, 50-75 ng/ml, 75-100 ng/ml, 100-150 ng/ml, 150-300 ng/ml and 300-500 ng/ml.
  • the preferred concentration of Wnt3a that is added to the cells is about 50 ng/ml.
  • the duration of Wnt3a exposure used in the examples is two days. However, this may be changed to three, four, five or six days.
  • the concentration of Activin A that is added to the cells can range from about 10 ng/ml to about 1000 ng/ml. However, the invention also encompasses sub-ranges of concentrations of Activin A. For example, from about 10-25 ng/ml, 25-50 ng/ml, 50-75 ng/ml, 75-100 ng/ml, 100-125 ng/ml, 125-150 ng/ml, 150-175 ng/ml, 175-200 ng/ml, 200-400 ng/ml, 400-600 ng/ml, 600-800 ng/ml and 800-1000 ng/ml.
  • the preferred concentration of Activin A that is added to the cells is about 100 ng/ml.
  • the duration of Activin A exposure used in the examples is four days (two days in the presence of Wnt3 A followed by two more days in the absence of Wnt3A). However, this may be changed to five, six or seven days.
  • the hepatic differentiation factor BMP4 is added to the cells.
  • concentration of BMP4 that is added to the cells can range from about 5 ng/ml to about 500 ng/ml. However, the invention also encompasses sub-ranges of concentrations of BMP4.
  • ng/ml from about 5-10 ng/ml, 10-20 ng/ml, 20-30 ng/ml, 30-40 ng/ml, 40-50 ng/ml, 50-60 ng/ml, 60-70 ng/ml, 70-80 ng/ml, 80-90 ng/ml, 90-100 ng/ml, 100-200 ng/ml, 200-300 ng/ml, 300-400 ng/ml and 400-500 ng/ml.
  • the preferred concentration of BMP4 that is added to the cells is about 50 ng/ml.
  • the duration of BMP4 exposure used in the examples is four days. However, this may be changed to five, six, or seven days.
  • the hepatic differentiation factor FGFl (also indicated as aFGF) is added to the cells.
  • the concentration of FGFl that is added to the cells can range from about 5 ng/ml to about 500 ng/ml. However, the invention also encompasses sub-ranges of concentrations of FGFl . For example, from about 5-10 ng/ml, 10-20 ng/ml, 20-30 ng/ml, 30-40 ng/ml, 40-50 ng/ml, 50-60 ng/ml, 60-70 ng/ml, 70-80 ng/ml, 80-90 ng/ml, 90-100 ng/ml, 100-200 ng/ml, 200-300 ng/ml, 300-400 ng/ml and 400-500 ng/ml.
  • the preferred concentration of FGFl that is added to the cells is about 50 ng/ml.
  • the duration of aFGF exposure used in the examples is four days. However, this may be changed to five, six, or seven days.
  • the hepatic differentiation factor HGF is added to the cells.
  • the concentration of HGF that is added to the cells can range from about 2 ng/ml to about 200 ng/ml. However, the invention also encompasses sub-ranges of concentrations of HGF. For example, from about 2-5 ng/ml, 5-10 ng/ml, 10-15 ng/ml, 15-20 ng/ml, 20-25 ng/ml, 25- 30 ng/ml, 30-35 ng/ml, 35-40 ng/ml, 40-50 ng/ml, 50-100 ng/ml, 100-150 ng/ml and 150-200 ng/ml.
  • the preferred concentration of HGF that is added to the cells is about 20 ng/ml.
  • the duration of HGF exposure used in the examples is 16 days. However, this may be changed to four, five, six, seven, eigth, nine, ten, eleven, twelf, thirteen, fourteen and fifteen days and can be as high as 30 days.
  • the present invention can be practiced, preferably, using stem cells of vertebrate species, such as humans, non-human primates, domestic animals, livestock, and other non-human mammals.
  • ES and EG cells have been identified in most tissues.
  • the most well studied stem cell is the embryonic stem cell (ESC), as it has unlimited self-renewal and multipotent differentiation potential. These cells are derived from the inner cell mass of the blastocyst or can be derived from the primordial germ cells of a post-implantation embryo (embryonal germ cells or EG cells).
  • ES and EG cells have been derived, first from mouse, and later, from many different animals, and more recently, from non-human primates and humans. When introduced into mouse blastocysts or blastocysts of other animals, ESCs can contribute to all tissues of the animal.
  • ES and EG cells can be identified by positive staining with antibodies against SSEA1 (mouse) and SSEA4 (human).
  • Oct4 belongs to the POU (Pit- Oct-Unc) family of transcription factors and is a DNA binding protein that is able to activate the transcription of genes, containing an octameric sequence called "the octamer motif within the promotor or enhancer region. Oct4 is expressed at the moment of the cleavage stage of the fertilized zygote until the egg cylinder is formed.
  • Oct3/4 The function of Oct3/4 is to repress differentiation inducing genes (i.e., FoxaD3, hCG) and to activate genes promoting pluripotency (FGF4, Utfl, Rexl).
  • Sox2 a member of the high mobility group (HMG) box transcription factors, cooperates with Oct4 to activate transcription of genes expressed in the inner cell mass. It is essential that Oct3/4 expression in embryonic stem cells is maintained between certain levels. Overexpression or downregulation of >50% of Oct4 expression level will alter embryonic stem cell fate, with the formation of primitive endoderm/mesoderm or trophectoderm, respectively. In vivo, Oct4 deficient embryos develop to the blastocyst stage, but the inner cell mass cells are not pluripotent.
  • Sall4 a mammalian Spalt transcription factor
  • Oct4 is an upstream regulator of Oct4
  • is an upstream regulator of Oct4 When Sall4 levels fall below a certain threshold, trophectodermal cells will expand ectopically into the inner cell mass.
  • Another transcription factor required for pluripotency is Nanog, named after a Celtic tribe "Tir Nan Og”: the land of the ever young. In vivo, Nanog is expressed from the stage of the compacted morula, is subsequently defined to the inner cell mass and is downregulated by the implantation stage.
  • Nanog null embryos isolated at day 5.5, consist of a disorganized blastocyst, mainly containing extraembryonic endoderm and no discernable epiblast.
  • ADSCs adipose-derived adult stem cells
  • MSCs derived from bone marrow
  • a method of isolation has been described in U.S. 2005/0153442.
  • non-embryonic cells reported to be capable of differentiating into cell types of more than one embryonic germ layer include, but are not limited to, cells from umbilical cord blood (see U.S. Publication No. 2002/0164794), placenta (see U.S. Publication No. 2003/0181269; umbilical cord matrix (Mitchell, K.E. et al, Stem Cells, 21 :50-60, 2003), small embryonic-like stem cells (Kucia, M.
  • amniotic fluid stem cells (Atala, A., J Tissue Regen Med, 1 :83-96, 2007), skin-derived precursors (Toma et al, Nat Cell Biol, 3:778-784, 2001), and bone marrow (see U.S. Publication Nos. 2003/0059414 and 2006/0147246), each of which is incorporated by reference herein for teaching these cells.
  • stem cells that are known in the art include gastrointestinal stem cells, epidermal stem cells, and hepatic stem cells, which also have been termed "oval cells” (Potten, C, et al, Trans R Soc Lond B Biol Sci, 353:821-830 (1998);, Watt, F., Trans R Soc Lond B Biol Sci, 353:831 (1997); Alison et al, Hepatology, 29:678-683 (1998).
  • oval cells Potten, C, et al, Trans R Soc Lond B Biol Sci, 353:821-830 (1998);, Watt, F., Trans R Soc Lond B Biol Sci, 353:831 (1997); Alison et al, Hepatology, 29:678-683 (1998).
  • Nuclear transfer involves the injection of a somatic nucleus into an enucleated oocyte, which, upon transfer into a surrogate mother, can give rise to a clone ("reproductive cloning"), or, upon explantation in culture, can give rise to genetically matched embryonic stem (ES) cells ("somatic cell nuclear transfer," SCNT).
  • ES embryonic stem
  • somatic cells in culture selects for immortal cell lines that may be pluripotent or multipotent.
  • spermatogonial stem cells are the only source of pluripotent cells that can be derived from postnatal animals.
  • Transduction of somatic cells with defined factors can initiate reprogramming to a pluripotent state.
  • Nuclear transplantation also referred to as somatic cell nuclear transfer (SCNT) denotes the introduction of a nucleus from a donor somatic cell into an enucleated ogocyte to generate a cloned animal such as Dolly the sheep (Wilmut et al, Nature, 385:810-813 (1997).
  • the generation of live animals by NT demonstrated that the epigenetic state of somatic cells, including that of terminally differentiated cells, while stable, is not irreversible fixed but can be reprogrammed to an embryonic state that is capable of directing development of a new organism.
  • nuclear cloning technology is of potential interest for patient-specific transplantation medicine.
  • human ES cells have the potential to reprogram somatic nuclei after fusion (Cowan et al, Science, 309: 1369-1373(2005)); Yu et al, Science, 318:1917-1920 (2006)).
  • Activation of silent pluripotency markers such as Oct4 or reactivation of the inactive somatic X chromosome provided molecular evidence for reprogramming of the somatic genome in the hybrid cells.
  • Pluripotent cells have been derived from embryonic sources such as blastomeres and the inner cell mass (ICM) of the blastocyst (ES cells), the epiblast (EpiSC cells), primordial germ cells (EG cells), and postnatal spermatogonial stem cells (“maGSCsm” "ES-like” cells).
  • ICM inner cell mass
  • ES cells blastocyst cells
  • EpiSC cells epiblast cells
  • EG cells primordial germ cells
  • maGSCsm postnatal spermatogonial stem cells
  • parthogenetic ES cells are derived from murine oocytes (Narasimha et al, Curr Biol, 7:881-884 (1997)); embryonic stem cells have been derived from blastomeres (Wakayama et al., Stem Cells, 25:986-993 (2007)); inner cell mass cells (source not applicable) (Eggan et al, Nature, 428:44-49 (2004)); embryonic germ and embryonal carcinoma cells have been derived from primordial germ cells (Matsui et al, Cell, 70:841-847 (1992)); GMCS, maSSC, and MASC have been derived from spermatogonial stem cells (Guan et al, Nature, 440:1199-1203 (2006); Kanatsu-Shinohara et al, Cell, 119: 1001-1012 (2004); and Seandel et al, Nature, 449:346-350 (2007)); EpiSC cells are derived from murine oocytes (Narasimha et al,
  • Donor cells from the germ cell lineage such as PGCs or spermatogonial stem cells are known to be unipotent in vivo, but it has been shown that pluripotent ES-like cells (Kanatsu-Shinohara et al, Cell, 119: 1001-1012 (2004) or maGSCs (Guan et al, Nature, 440: 1199-1203 (2006), can be isolated after prolonged in vitro culture.
  • multipotent adult spermatogonial stem cells were derived from testicular spermatogonial stem cells of adult mice, and these cells had an expression profile different from that of ES cells (Seandel et al., Nature, 449:346-350 (2007)) but similar to EpiSC cells, which were derived from the epiblast of postimplantation mouse embryos (Brons et al, Nature, 448:191-195 (2007); Tesar et al, Nature, 448: 196-199 (2007)).
  • oncogenes may, in fact, be dispensable for reprogramming, as both mouse and human iPS cells have been obtained in the absence of c-myc transduction, although with low efficiency (Nakagawa et al, Nat Biotechnol, 26:191-106 (2008); Werning et al, Nature, 448:318-324 (2008); Yu et al, Science, 318: 1917-1920 (2007)).
  • MAPC is an acronym for "multipotent adult progenitor cell” (non-ES, non-EG, non-germ). Genes found in ES cells also have been found in MAPCs (e.g., telomerase, Oct 3/4, rex-1, rox-1, sox-2). Oct 3/4 (Oct 3 A in humans) appears to be specific for ES and germ cells.
  • MAPC represents a more primitive progenitor cell population than MSC and demonstrates differentiation capability encompassing the epithelial, endothelial, neural, myogenic, hematopoietic, osteogenic, hepatogenic, chondrogenic and adipogenic lineages
  • Verfaillie, CM., Trends Cell Biol, 12:502-8, 2002 Jahagirdar, B.N., et al, Exp Hematol, 29:543-56, 2001; Reyes, M. and CM. Verfaillie, Ann N Y Acad Sci, 938:231-233, 2001; Jiang, Y. et al, Exp Hematol, 30896-904, 2002; and Jiang, Y. et al, Nature, 418:41-9, 2002).
  • cells useful for the invention can be maintained and expanded in culture medium that is available to and well-known in the art.
  • Such media include, but are not limited to, Dulbecco's Modified Eagle's Medium® (DMEM), DMEM F12 medium®, Eagle's Minimum Essential Medium®, F-12K medium®, Iscove's Modified Dulbecco's Medium® and RPMI-1640 medium®.
  • DMEM Dulbecco's Modified Eagle's Medium
  • F12 medium Eagle's Minimum Essential Medium®
  • F-12K medium F-12K medium
  • Iscove's Modified Dulbecco's Medium® RPMI-1640 medium®.
  • Many media are also available as low-glucose formulations, with or without sodium pyruvate.
  • Also contemplated in the present invention is supplementation of cell culture medium with mammalian sera.
  • mammalian sera concentrations range between 0% and 2%, more particularly the serum concentration is 0%.
  • Sera often contain cellular factors and components that are necessary for viability and expansion. Examples of sera include fetal bovine serum (FBS), bovine serum (BS), calf serum (CS), fetal calf serum (FCS), newborn calf serum (NCS), goat serum (GS), horse serum (HS), human serum, chicken serum, porcine serum, sheep serum, rabbit serum, serum replacements and bovine embryonic fluid. It is understood that sera can be heat-inactivated at 55-65°C if deemed necessary to inactivate components of the complement cascade.
  • Additional supplements also can be used advantageously to supply the cells with the necessary trace elements for optimal growth and expansion.
  • Such supplements include insulin, transferrin, sodium selenium and combinations thereof.
  • These components can be included in a salt solution such as, but not limited to, Hanks' Balanced Salt Solution® (HBSS), Earle's Salt Solution®, antioxidant supplements, MCDB-201® supplements, phosphate buffered saline (PBS), ascorbic acid and ascorbic acid-2-phosphate, as well as additional amino acids.
  • HBSS Hanks' Balanced Salt Solution®
  • PBS phosphate buffered saline
  • Ascorbic acid and ascorbic acid-2-phosphate as well as additional amino acids.
  • Many cell culture media already contain amino acids, however, some require supplementation prior to culturing cells.
  • Such amino acids include, but are not limited to, L-alanine, L-arginine, L-aspartic acid, L-asparagine, L-cysteine, L-cystine, L- glutamic acid, L-glutamine, L-glycine, L-histidine, L-isoleucine, L-leucine, L-lysine, L- methionine, L-phenylalanine, L-proline, L-serine, L-threonine, L-tryptophan, L-tyrosine, and L-valine. It is well within the skill of one in the art to determine the proper concentrations of these supplements.
  • Hormones also can be advantageously used in the cell cultures of the present invention and include, but are not limited to, D-aldosterone, diethylstilbestrol (DES), dexamethasone, ⁇ - estradiol, hydrocortisone, insulin, prolactin, progesterone, somatostatin/human growth hormone (HGH), thyrotropin, thyroxine and L-thyronine.
  • DES diethylstilbestrol
  • dexamethasone ⁇ - estradiol
  • hydrocortisone insulin
  • prolactin progesterone
  • HGH somatostatin/human growth hormone
  • thyrotropin thyroxine
  • L-thyronine L-thyronine
  • Lipids and lipid carriers also can be used to supplement cell culture media, depending on the type of cell and the fate of the differentiated cell.
  • Such lipids and carriers can include, but are not limited to, cyclodextrin ( ⁇ , ⁇ , ⁇ ), cholesterol, linoleic acid conjugated to albumin, linoleic acid and oleic acid conjugated to albumin, unconjugated linoleic acid, linoleic-oleic- arachidonic acid conjugated to albumin and oleic acid unconjugated and conjugated to albumin, among others.
  • feeder cell layers Feeder cells are used to support the growth of fastidious cultured cells such as ES cells.
  • Feeder cells are normal cells that have been inactivated by ⁇ -irradiation. In culture, the feeder layer serves as a basal layer for other cells and supplies cellular factors without further growth or division of their own (Lim, J.W. and Bodnar, A., 2002). Examples of feeder layer cells are typically human diploid lung cells, mouse embryonic fibroblasts and Swiss mouse embryonic fibroblasts, but can be any post-mitotic cell that is capable of supplying cellular components and factors that are advantageous in allowing optimal growth, viability and expansion of stem cells. In many cases, feeder cell layers are not necessary to keep ES cells in an undifferentiated, proliferative state, as leukemia inhibitory factor (LIF) has anti- differentiation properties. Therefore, supplementation with LIF can be used to maintain MAPC in some species in an undifferentiated state.
  • LIF leukemia inhibitory factor
  • Cells may be cultured in low-serum or serum-free culture medium.
  • Serum-free medium used to culture MAPCs is described in U.S. Patent 7,015,037. Many cells have been grown in serum-free or low-serum medium.
  • the medium is supplemented with one or more growth factors.
  • Commonly used growth factors include, but are not limited to, bone morphogenic protein, basis fibroblast growth factor, platelet-derived growth factor and epidermal growth factor. See, for example, U.S. Patent Nos.
  • Cells in culture can be maintained either in suspension or attached to a solid support, such as extracellular matrix components.
  • Stem cells often require additional factors that encourage their attachment to a solid support, such as type I and type II collagen, chondroitin sulfate, fibronectin, "superfibronectin” and fibronectin-like polymers, gelatin, poly-D and poly-L- lysine, thrombospondin and vitronectin.
  • One embodiment of the present invention utilizes fibronectin.
  • Cells may also be grown in "3D" (aggregated) cultures.
  • 3D aggregated
  • cells can be used fresh or frozen and stored as frozen stocks, using, for example, DMEM with 40% FCS and 10% DMSO.
  • DMEM fetal calf serum
  • FCS fetal calf serum
  • DMSO fetal calf serum
  • Methods of identifying and subsequently separating differentiated cells from their undifferentiated counterparts can be carried out by methods well known in the art.
  • Cells that have been induced to differentiate using methods of the present invention can be identified by selectively culturing cells under conditions whereby differentiated cells outnumber undifferentiated cells.
  • differentiated cells can be identified by morphological changes and characteristics that are not present on their undifferentiated counterparts, such as cell size and the complexity of intracellular organelle distribution.
  • methods of identifying differentiated cells by their expression of specific cell-surface markers such as cellular receptors and transmembrane proteins. Monoclonal antibodies against these cell-surface markers can be used to identify differentiated cells.
  • Detection of these cells can be achieved through fluorescence activated cell sorting (FACS) and enzyme-linked immunosorbent assay (ELISA). From the standpoint of transcriptional upregulation of specific genes, differentiated cells often display levels of gene expression that are different from undifferentiated cells. Reverse-transcription polymerase chain reaction, or RT-PCR, also can be used to monitor changes in gene expression in response to differentiation. Whole genome analysis using microarray technology also can be used to identify differentiated cells.
  • the methods of identification detailed above also provide methods of separation, such as FACS, preferential cell culture methods, ELISA, magnetic beads and combinations thereof.
  • FACS preferential cell culture methods
  • ELISA ELISA
  • magnetic beads and combinations thereof.
  • One embodiment of the present invention comtemplates the use of FACS to identify and separate cells based on cell-surface antigen expression.
  • the liver plays a major role in metabolism, including plasma protein synthesis (e.g. albumin and coagulation factors), glycogen storage, decomposition of red blood cells, and detoxification.
  • plasma protein synthesis e.g. albumin and coagulation factors
  • glycogen storage e.g. glycogen storage
  • decomposition of red blood cells e.g. detoxification.
  • One of the major impediments to the use of hepatocytes in at least one area of medicine is, in general, the scarcity of human hepatocytes that are available, eg. for developing a screening system of hepatotropic virus infectable (and replication supportable) cells which can be used to screen for antiviral drugs, more in particular hepatitis drugs and more particularly inhibitors of HCV.
  • such cells (hepatocytes) can be used to screen for drugs for other (non-viral) hepatotropic pathogens as well.
  • the limited availability of human tissue and also subject to the variability of the source material impedes these types of studies.
  • the cells of the invention can be used in such studies and in drug development.
  • cell culture conditions were developed in view of (marker)gene expression and optimized from conditions that were previously developed (Roelandt, P., et al. 2010, and WO2010049752), for a detailed description, see Example 1 and Figure 3 in this specification.
  • the inventors developed specific cell culture conditions to successfully produce cells that express phenotypes of hepatocytes.
  • Next to the use in the hepatitis field, such (hepatocyte) differentiated cells are useful, amongst others, in the field of therapy of liver failure and for pharmaceutical testing.
  • liver failure is caused by a number of disorders, including cirrhosis due to infections, excessive alcohol consumption, genetic and idiopatic reasons.
  • liver failure is caused by ingestion of certain drugs or foods.
  • Liver transplantation is the only successful treatment for end stage liver disease, and is in many instances also the only curative therapy for certain forms of genetic disorders of the liver.
  • Many liver disorders treated by whole liver transplantation result from hepatocyte dysfunction.
  • hepatocyte transplantation has been great interest in hepatocyte transplantation for the treatment of acute and chronic liver failure, as well as inherited metabolic disorders.
  • grafted hepatocytes can assume the full range of liver functions in vivo.
  • Hepatocyte transplantation has several advantages over whole liver transplant: lower morbidity, a single donor organ can be used for several recipients, cells can be cryopreserved, and cells grafts are less immunogenic than whole organ grafts. However, lack of donor cells curtails further exploration of this therapy.
  • the invention is also directed to methods of treating liver deficiencies by administering the (differentiated) cells of the invention to a subject with the liver deficiency.
  • liver deficiencies include, but are not limited to, toxic liver disease, metabolic liver disease, acute liver necrosis, effects of acetaminophen, hemochromatosis, Wilson's Disease, Crigler Najar, hereditary tyrosinemia, familial intrahepatic cholestatis type 3, ornithine transcarbamylase (OTC) deficiency, and urea cycle disorder.
  • Further diseases include, but are not limited to viral hepatitis, chronic viral hepatitis A, B, C, acute hepatitis A, B, C, D, E, cytomegalovirus and herpes simplex virus; liver dysfunction in other infectious diseases such as, without limitation, toxoplasmosis, hepatosplenic schistosomiasis, liver disease in syphilis, leptospirosis and amoebiasis; metabolic diseases such as, without limitation, haemochromatosis, Gilbert's syndrome, Dubin- Johnson syndrome and Rotor's syndrome; alcoholic liver disease such as, without limitation, fatty liver, fibrosis, sclerosis and cirrhosis; and toxic liver disease.
  • Bioartificial liver (BAL) devices include, but are not limited to viral hepatitis, chronic viral hepatitis A, B, C, acute hepatitis A, B, C, D, E, cytomegalovirus and herpes simplex virus
  • BAL devices are designed to support the detoxification functions performed by the liver, hence decreasing the risk and severity of CNS complications associated with acute liver failure. BAL devices could benefit three groups of patients; those with fulminant hepatic failure, those waiting for an imminent transplant, and those with early failure of a liver transplant. Although some positive results have been seen in patients with liver failure, further exploration of the usefulness of BAL devices has been hampered by lack of suitable cells. Currently, tumor-derived cell lines or animal cells, which might be associated with possible tumor cell seeding, immune responses, and xeno-zoonoses, are used.
  • the availability of cells with full mature hepatic function of human origin would enable investigators to further test and optimize BAL devices to bridge patients till the liver spontaneously regenerates or a donor-liver is available. Although clinical trials have in general not been successful, some encouraging results have been seen in patients with acute liver failure. Accordingly, the (differentiated) cells of the invention can be used in such bioartificial liver devices.
  • the (differentiated) cells of the invention can be used in such testing methods.
  • the present invention is additionally described by way of the following illustrative, non- limiting example that provides a better understanding of the present invention and of its many advantages.
  • hESC-H9 and hESC-Hl, WiCell, Madison, WI Human embryonic stem cells
  • iPSC derived by co-transduction with OCT4, SOX2, KLF4 and cMYC in the fibroblast cell line BJ1
  • the iPSC line was characterized by embryoid body and teratoma formation, and could undergo directed differentiation to hepatocyte- and neuron-like cells as determined by RT-qPCR and immunostaining.
  • the transgenes were silenced, as determined by RT- qPCR.
  • HCV JFH cell-culture mutant virus described by Delgrange et a/.2007, was used with a specific-infectivity titer of 1 :400 (ratio between FFU/mL:HCV RNA copies number Zhong, J., et al. 2006).
  • hSC were differentiated towards liver-specific progeny using a modified and optimized differentiation protocol, as compared to the initial protocol described earlier (Roelandt, P., et al. 2010, and WO2010049752) ( Figure 3).
  • the optimized protocol used in this studay ActA (100ng/ml)-Wnt3A (50ng/ml) day 0-2, ActA (lOOng/ml) day 2-4, BMP4 (50ng/ml) day 4-8, FGF1 (50ng/ml) day 8-12, HGF (20ng/ml) day 12-28, and no serum was added during the complete optimized protocol.
  • ActA 100ng/ml
  • ActA (lOOng/ml) day 2-4
  • BMP4 (50ng/ml) day 4-8 50ng/ml) day 4-8
  • FGF1 50ng/ml
  • HGF (20ng/ml) day 12-28 HGF (20ng/ml) day 12-28
  • no serum was added during the complete optimized protocol.
  • Huh7.5.1 cells were used as controls.
  • HCV virus stock for 48h at 37°C. Following two to three washes, fresh medium was added for additional 72h.
  • HCV NS3 protease inhibitor VX-950 and the non-nucleoside NS5B polymerase inhibitor (benzofuran) HCV-796 were synthesized as described before (references in Paeshuyse J, et al, 2008). Supernatants were collected every 3 days. 2.
  • hSC progeny was fixed using 4% Neutral Buffered Formalin (NBF) for 15 minutes at room temperature. Permeabilization and blocking was done for 15 minutes using phosphate buffered saline (PBS) containing 0.2% Triton X-100 (Acros Organics) and 3% donkey serum (Jackson). The cells were then incubated with the mixture of primary antibodies diluted in PBS overnight at 4°C. After three washes with PBS, the cells were incubated with the mixture of secondary antibodies and Hoechst (Sigma) for 30 minutes at room temperature.
  • NAF Neutral Buffered Formalin
  • mice anti-CD81 (BD Biosciences 555675, 1 : 100), rabbit anti-SR-Bl (Abeam AB3, 1 : 1000), mouse anti-HNF4a (Abeam AB41898, 1 :200), rabbit anti-ALB (Dako A0001, 1 :4000), mouse anti-CYP3A4/5 (BD Biosciences WB-MAB-3A, 1 :250) and rabbit anti-HCV NS5A (a kind gift of Prof. R. Bartenschlager, 1 :2000).
  • Isotypes mouse IgGi (BD Biosciences 550878), mouse IgG 2 A (Sigma M9144), rabbit serum (Dako X0902).
  • RNA isolation from uninfected hSC-progeny the RNeasy Mini-kit/Micro-kit (Qiagen) was used. DNase treatment was performed using Turbo DNase kit (Ambion). cDNA synthesis was performed from 1 ⁇ g of RNA with Superscript III First-Strand synthesis system (Invitrogen). RT-qPCR was performed with SYBR Green Platinum SYBR green qPCR Supermix-UDG (Invitrogen) in an Eppendorf Realplex/ABI 7000 (Eppendorf) equipment.
  • RT-qPCR primers CD81 (forward 5'-ATG TGA AGC AGT TCT ATG ACC-3', reverse 5'-TCA TCT CGA AGA TCA TGA TCA C-3'), CLDNl (forward 5'-GCG CGA TAT TTC TTC TTG CAG-3', reverse 5'-GCA GGT TTT GGA TAG GGC CT-3'), CLDN6 (forward 5'-AGA AGG ATT CCA AGG CCC G-3', reverse 5'-GAT GTT GAG TAG CGG GCC AT-3'), LDL-R (forward 5'-CAA GGA CAA ATC TGA CGA GG-3', reverse 5'-AGA GTG TCA CAT TAA CGC AG-3') and SR-B1 (forward 5'-TGA ACT GCT CTG TGA AAC TG-3', reverse 5'-AAT AGC ATT TCT CTT GGC TCC-3').
  • a 25 ⁇ RT-qPCR contains 6.25 ⁇ of 2x reaction buffer (Eurogentec), 12.65 ⁇ H 2 0, 5 ⁇ total cellular R A extract and 200 nmol/L SF-JFH86 (5'-TGG CGT TAG TAT GAG TGT CGT AC A GCC TCC A-3'), and 200 nmol/L SR-JFH194 (5 '-AAA GGA CCC AGT CTT CCC GGC AAT T-3'), and 6 pmol/L prob (5'-FAM-TGG TCT GCG GAA CCG GTG AGT ACA CC-TAMRA-3').
  • hSC-progeny was washed twice with PBS and scraped to obtain cell clusters.
  • the fragments were fixed in 2.5% glutaraldehyde in 0.1 M cacodylate.
  • the samples were dehydrated in graded series of alcohol and embedded in epoxy resin. Ultrathin sections were cut, stained with uranyl acetate and lead citrate, and examined using a Zeiss EM 900 electron microscope (Oberkochen, Germany).
  • HCV core protein and ApoBlOO were measured using Ortho® HCV core antigen ELISA (Wako Chemicals) and Alerchek's Human ApoBlOO ELISA, respectively, as previously described (Nahmias, Y., et al. 2008). 6. Secondary infection immunofluorescence assay
  • the collected supernatants were used to inoculate na ' ive Huh7.5.1 in 8 well chamber slides (100 ⁇ in 300 ⁇ complete DMEM medium). After 72 hours, the medium was removed and cells were washed twice with PBS, fixed for 20 minutes with 3.5%> paraformaldehyde and permeabilized with 0.5% Triton X-100 for 15 minutes. Cells were washed with PBS then blocked for 20 minutes at room temperature with IT-Image signal enhancer (Invitrogen) and incubated with rabbit polyclonal anti-HCV NS5A antibody (1 :2000) diluted in 5% normal goat serum for 60 minutes, followed by goat anti-rabbit Alexa 488 (Invitrogen) for 45 minutes in dark. Finally, cells were washed for 10 minutes in PBS and maintained in prolong antifade mounting medium with DAPI (Invitrogen). 7. Statistics
  • hepatocytes derived from human embryonic stem cells (hESC) (H9 and HI cells) or hiPSC can support the complete HCV replication cycle including the production of infectious virus.
  • cytoplasmic localization of NS5A could be demonstrated in 14.7 ⁇ 12.7% of ALB + and CYP3A4/5 + hepatocytes, indicating that HCV entry as well as transcription of the original viral RNA by the host cell ribosomes was successful (Data not shown).
  • Nuclear localization of NS5A was also noted in 14.2 + 18.6% of ALB + and CYP3A4/5 + hepatocytes, suggestive of nuclear translocation of NS5A.
  • the replication of HCV RNA could be inhibited by the addition of 10 ⁇ HCV-796 (97.9% inhibition) or 1 ⁇ VX-950 (74.2% inhibition) ( Figure 4).
  • Viral R A replication occurs on modified intracellular membranes, forming a membranous web. Swollen endoplasmatic reticulum (ER), double-membrane and multi-membrane vesicles were observed by means of electron microscopy in HCV-infected hSC-progeny (Data not shown).
  • Newly produced HCV is packed in very low density (VLDL)- and low density (LDL)- lipoviroparticles, consisting mainly of apolipoprotein B-100 (ApoBlOO).
  • Albumin, ApoBlOO and HCV core protein was secreted in the supematants of infected hSC-progeny at a relatively constant rate over time, indicating stable replication (Figure 2B).
  • FPvhK-4 cells ATCC CRL-1688
  • BS-C-1 cells ATCC CCL-26
  • DMEM Dulbecco's modified Eagle's medium
  • FBS fetal bovine serum
  • Hepatitis A virus (HAV) strain HM 175/18f ATCC VR-1402, Lemon et al, 1991 was grown in BS-C-1 cells in DMEM with 2% FBS at 35°C.
  • Virus was harvested by 3 freeze-thaw cycles followed by centrifugation at lOOOg for 10 minutes at 4°C.
  • Interferon Interferon-alpha 2b (IFNa, Intron-A®) was purchased from Schering Plough (Kenilworth, NJ), diluted to 3.10 5 international units (IU)/mL in phosphate-buffered saline (PBS; Lonza, Venders, Belgium) supplemented with 10% glycerol and 0.1 %> bovine serum albumin, stored at -80°C and kept at 4°C after thawing.
  • PBS phosphate-buffered saline
  • bovine serum albumin stored at -80°C and kept at 4°C after thawing.
  • HM175/18f virus samples were titrated by end-point dilution.
  • FRhK-4 cells were seeded in 96-well plates (BD Falcon; Franklin Lakes, NJ) at 2.10 4 cells per well in ⁇ of DMEM supplemented with 2% FBS and incubated at 37°C. After 24h, cells were confluent, medium was removed and ⁇ of a 1 : 10 virus dilution series in medium was added to each well. Each dilution was analyzed in 2-fold. Plates were incubated at 35°C for 7 days and subsequently scored by microscopy for cytopathic effect (CPE).
  • CPE cytopathic effect
  • the tissue culture infectious dose 50 corresponds to a viral dose sufficient to induce CPE in half of the cells in a tissue culture and was calculated by the method of Reed and Muench (Reed et al, 1938). 3. Infection of stem cell-derived hepatocytes
  • the differentiation protocol was performed for a 12-well plate as described. At 18 days post start of differentiation (d.p.s.d.), cells were transferred to 35°C. Pretreatment with IFNa at 300 IU/mL was started for 3 wells at 21 d.p.s.d.. The following day, medium was removed and to 3 non-treated and 3 IFNa-treated wells, ImL of a HM175/18f dilution in liver differentiation medium (LDM) supplemented with hepatocyte growth factor (HGF) was added, corresponding to 1.39xl0 5 TCID 50 per well. Additionally, IFNa was added to the pretreated wells to a final concentration of 300 IU/mL.
  • LDM liver differentiation medium
  • HGF hepatocyte growth factor
  • Viral RNA was extracted from culture medium with the NucleoSpin RNA virus kit (Macherey-Nagel, Diiren, Germany) according to the manufacturer's instructions. Primers and probes for TaqMan-based quantification of HAV RNA were based on published sequences (Silberstein et al, 2003). As a forward primer 5'- GGCATTTAGGTTTTTCCTCATTCTTA-3 ' was used and the reverse primer was 5'- AATGTCTGCCAAAGACAGGATGT-3 ' .
  • the TaqMan probe was labeled with 6- carboxyfluorescein (FAM) at the 5 ' end and with a minor groove binder (MGB) at the 3 ' end (5 ' -6F AM-C AAGGTATTTTCC AG ACTGTTGGGAGTGGTCT-MGBNFQ-3 '). Reactions were performed with One-Step qRT-PCR mix (Eurogentec, Seraing, Belgium) in a final volume of 25 containing 3 ⁇ of each primer, 67nM of probe and 5 ⁇ ⁇ of RNA sample.
  • FAM 6- carboxyfluorescein
  • MGB minor groove binder
  • PCR was performed using the ABI 7500 Fast Real-Time PCR System (Applied Biosystems; Foster City, CA) under following conditions: 30 min at 48°C and 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. Data were analyzed with ABI PRISM 7500 SDS software (version 1.3.1, Applied Biosystems). For absolute quantification, standard curves were generated using 10-fold dilutions of template preparations of known concentrations.
  • DENV Dengue Fever Virus serotype 2 New Guinea C [DENV-2 NGC] were cultured on C6/36 mosquito cells (from Aedes albopictus; American Type Culture Collection at 28°C.
  • Yellow fever virus (YFV) 17D vaccine strain (Stamaril®) [Aventis Pasteur (MSD, Belgium)] was passaged once in Vero-B cells to prepare a working virus stock and stored at -80°C until further use. 2. Monitoring YFV and DENV replication.
  • the differentiation protocol was performed for a 12-well plate as described. At x days post start of differentiation (d.p.s.d) medium was removed and ImL of a diluted virus stock [either DENV-2 (NGC) or YFV-17D] in liver differentiation medium (LDM) supplemented with hepatocyte growth factor (HGF) was added. To 2 wells serving as cell control (CC), ImL of plain LDM with HGF was added. The cultures were incubated for 4h after which the inoculum was removed and cell layers were washed 5 times with plain DMEM to remove non-adsorbed virus and cultures were further incubated. One mL of LDM with HGF was added to each well.
  • NTC DENV-2
  • HGF hepatocyte growth factor
  • the TaqMan probe was fluorescently labeled with 6-carboxyfluorescein (FAM) at the 5' end as the reporter dye and with minor groove binder (MGB) at the 3' end as the quencher.
  • FAM 6-carboxyfluorescein
  • MGB minor groove binder
  • One-step, quantitative RT-PCR was performed in a total volume of 25 ⁇ , containing 13.9375 ⁇ H20, 6.25 ⁇ master mix (Eurogentec, Belgium), 0.375 ⁇ forward primer, 0.375 ⁇ reverse primer, 1 ⁇ probe, 0.0625 ⁇ reverse transcriptase (Eurogentec) and 3 ⁇ sample.
  • RT- PCR was performed using the ABI 7500 Fast Real-Time PCR System (Applied Biosystems, Branchburg, NJ) using the following conditions: 30 min at 48°C and 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 1 min at 60°C.
  • the data was analyzed using the ABI PRISM 7500 SDS software (version 1.3.1; Applied Biosystems). For absolute quantification, standard curves were generated using 10-fold dilutions of template preparations of known concentrations. Viral antigen expression in infected cultures was monitored at x days post infection.
  • the malaria parasite exhibits a complex life cycle involving an insect vector and a vertebrate host.
  • Plasmodium species infect humans P. falciparum, P. vivax, P. ovale and P. malariae. All four species exhibit a similar life cycle with only minor variations.
  • a proportion of the liver-stage parasites from P. vivax and P. ovale go through a dormant period instead of immediately undergoing asexual replication. These hypnozoites will reactivate several weeks to months (or years) after the primary infection and are responsible for relapses.
  • the sporozoites are arrested by the circum sporozoite protein (CSP) on the sporozoit that interacts with thrombospondin-related anonymous protein; on hepatocytes, stellate cells and kupfer cells.
  • CSP circum sporozoite protein
  • TRAPs are very highly sulphated and therefore different from other tissues. In particular sulphation of the glycosaminoglycan chains at both the N- and O-positions is required for sporozoite adhesion to cells.
  • sporozoites invade kupfer cells and these infected kupfer cells pass through the endothelial barrier. Once in space of Disse, sporozoites invade sequentially multiple hepatocytes before invading and infecting the final hepatocyte. This requires specific lipases and pore forming proteins: sporozoite microneme protein essential for cell traversal (SPECT)l, SPECT2, cell traversal protein for ookinete and sporozoite (CelTOS) and the phospho lipase PbPL.
  • SPECT cell traversal
  • SPECT2 cell traversal protein for ookinete and sporozoite
  • CelTOS cell traversal protein for ookinete and sporozoite
  • HGF hepatocyte growth factor
  • receptors on hepatocytes to which the sporozoites bind include CD81 and SRB1.
  • the intracellular parasite undergoes an asexual replication known as exoerythrocytic schizogony within the hepatocyte. Exoerythrocytic schizogony culminates in the production of merozoites.
  • a number of Plasmodium specific molecules are needed, termed upregulated in infective sporozoites (UIS)3 and 4, and Pb36p, and hepatocyte-specific APOA1 is also required.
  • UAS infective sporozoites
  • Pb36p hepatocyte-specific APOA1
  • the merozoites leave the parasitophorous vacuole, intermix with the cell cytoplasm and then are released as merozomes.
  • the membrane is host cell derived and hence not seen by the immune system, allowing the merozoites to be transported to RBCs where they can infect. Infection of the liver causes no symptoms but is required for subsequent infection of RBS. Hence, mechanisms to prevent infection/replication of merozoites in the liver could stop infection and symptoms from blood cell death
  • Merozoites invade reticulocytes where they initially become larger. At that stage the detectable as 'ring form' because of its morphology. The trophozoite ingests host cytoplasm and causes degradation of hemoglobin into amino acids as food for the trophozoit. Subsequently the trophozoit undergoes several rounds of nuclear division without cytokinesis, resulting in the creation of the schizont. Merozoites the bud from the mature schizont, and the merozoites are released following rupture of the infected erythrocyte. Subsequently the merozoits can reinvade erythrocytes with a new blood-stage replicative cycle.
  • the typical episodic fever is the result of synchronous lysis of infected erythrocytes.
  • P. malariae exhibits a 72 hour periodicity, whereas the other three species exhibit 48 hour cycles.
  • P. falciparum may also cause continuous fever and is responsible for more morbidity and mortality than the other species.
  • pluripotent stem cell derived hepatocyte progeny is seeded into collagen-coated wells of 24-well plates in hepatic differentiation medium.
  • P. Vivax or P. Falciparum sporozoites are isolated from the salivary glands of infected Anopheles mosquitoes and added to the Hepatocyte culture. After an incubation period of 2 hours the sporozoite-containing medium is removed and fresh medium is added. Production of merozoites in the hepatocytes is followed. After 3-7 days cells are analyzed to detect presence of parasitophorous vacuole, and merozomes containing merozoites. Cells are assessed for cell death.
  • HAV hepatitis A virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Procédés de culture de cellules afin d'amener lesdites cellules à se différencier en cellules exprimant un phénotype d'hépatocyte et/ou un phénotype de progéniteur d'hépatocyte qui permettent la réplication complète des virus de l'hépatite et d'autres pathogènes hépatotropiques, notamment du virus de l'hépatite C (VHC). Plus particulièrement, l'invention porte sur des procédés de culture de cellules afin d'amener lesdites cellules à se différencier en cellules exprimant un phénotype endodermique définitif, un phénotype endodermique à détermination hépatique, un phénotype d'hépatoblaste et un phénotype d'hépatocyte qui peuvent être infectés par le virus de l'hépatite et permettre la réplication complète des virus de l'hépatite, en particulier du virus de l'hépatite C. L'invention concerne en outre la mise au point d'un outil pour la recherche, la découverte et la validation d'inhibiteurs de la réplication du VHC et d'autres pathogènes hépatotropiques, plus particulièrement de médicaments et thérapies antiviraux contre le VHC. L'invention concerne encore des procédés permettant d'induire la réplication de virus hépatotropiques in vitro, et plus particulièrement un essai simple de réplication in vitro de virus hépatotropiques qui permet la production abondante et continue de virus hépatotropiques infectieux, par ex. du virus hépatotropique VHC. Les cellules produites selon ces procédés sont donc utiles, entre autres choses, pour des études de toxicité et pour le criblage de traitements ou médicaments contre les virus de l'hépatite, plus particulièrement contre le virus de l'hépatite C.
PCT/EP2012/072316 2011-11-09 2012-11-09 Cellules souches pouvant être infectées par des virus WO2013068557A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1119335.6A GB201119335D0 (en) 2011-11-09 2011-11-09 Hepatitis virus infectable stem cells
GB1119335.6 2011-11-09

Publications (1)

Publication Number Publication Date
WO2013068557A1 true WO2013068557A1 (fr) 2013-05-16

Family

ID=45421502

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/072316 WO2013068557A1 (fr) 2011-11-09 2012-11-09 Cellules souches pouvant être infectées par des virus

Country Status (2)

Country Link
GB (1) GB201119335D0 (fr)
WO (1) WO2013068557A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016061298A1 (fr) * 2014-10-15 2016-04-21 Coyne Ip Holdings, Llc Procédés de conduite d'études stimulus-réponse avec des cellules souches pluripotentes induites dérivées de cellules ou de tissus périnataux
CN106754653A (zh) * 2017-03-06 2017-05-31 广州润虹医药科技有限公司 iPS细胞分化成内胚层祖细胞的无血清诱导培养基及诱导方法
CN107208060A (zh) * 2015-01-07 2017-09-26 先锋生药开发有限公司 应用人脂肪衍生的干细胞增殖血清来源的丙肝病毒及其用途
CN107916248A (zh) * 2016-10-06 2018-04-17 尼希尔株式会社 来源于人类干细胞的肝细胞分化方法及肝细胞
US11274279B2 (en) 2020-03-11 2022-03-15 Bit Bio Limited Method of generating hepatic cells

Citations (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2212108A (en) 1938-04-23 1940-08-20 Tidewater Associated Oil Compa Process of treating rotary mud
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US5397706A (en) 1991-11-06 1995-03-14 Correa; Paulo N. Serum-free basal and culture medium for hematopoietic and leukemia cells
US5453357A (en) 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5656479A (en) 1992-05-15 1997-08-12 North Carolina State University Avian embryonic stem cells
US5766951A (en) 1992-11-12 1998-06-16 Quality Biological, Inc. Serum-free medium supporting growth and proliferation of normal bone marrow cells
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5874301A (en) 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5908782A (en) 1995-06-05 1999-06-01 Osiris Therapeutics, Inc. Chemically defined medium for human mesenchymal stem cells
US5914268A (en) 1994-11-21 1999-06-22 National Jewish Center For Immunology & Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US6037174A (en) 1993-08-23 2000-03-14 Nexell Therapeutics, Inc. Preparation of serum-free suspensions of human hematopoietic cells or precursor cells
US6190910B1 (en) 1996-05-21 2001-02-20 The Institute Of Physical And Chemical Research Mouse embryonic stem cell lines
US6224860B1 (en) 1996-10-18 2001-05-01 Quality Biological, Inc. Method for repopulating human bone marrow comprising culturing CD34+ cells in a serum free medium
US6432711B1 (en) 1993-11-03 2002-08-13 Diacrin, Inc. Embryonic stem cells capable of differentiating into desired cell lines
US6436701B1 (en) 1988-09-21 2002-08-20 Babraham Institute Derivation of pluripotential embryonic cell lines from ungulate species
US20020164794A1 (en) 2000-11-03 2002-11-07 Peter Wernet Human cord blood derived unrestricted somatic stem cells (USSC)
US6500668B2 (en) 1994-10-21 2002-12-31 Jacques Samarut Culture medium for avian embryonic cells
US20030059414A1 (en) 2001-09-21 2003-03-27 Ho Tony W. Cell populations which co-express CD49c and CD90
US6617159B1 (en) 1998-11-09 2003-09-09 Consorzio Per La Gestione Del Centro Di Biotechnologie Avanzate Serum free medium for chondrocyte cells
US6617161B2 (en) 1997-06-25 2003-09-09 The United States Of America As Represented By The Department Of Health And Human Services Serum-free cell growth medium
US20030181269A1 (en) 2002-03-20 2003-09-25 Sara Griffin Portable, non-slip training aid for sports
US6703279B2 (en) 2002-01-04 2004-03-09 Promos Technologies, Inc. Semiconductor device having contact of Si-Ge combined with cobalt silicide
US6875607B1 (en) 1998-11-09 2005-04-05 Es Cell International Pte Ltd Embryonic stem cells
US20050153442A1 (en) 1999-03-10 2005-07-14 Adam Katz Adipose-derived stem cells and lattices
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US7037721B1 (en) 1990-01-29 2006-05-02 Hy-Gene Biomedical, Inc. Protein-free defined media for the growth of normal human keratinocytes
US20060147246A1 (en) 2002-09-16 2006-07-06 Richards John M Grip for hand held instruments
US7112437B2 (en) 2000-06-20 2006-09-26 Es Cell International Pte Ltd. Methods of culturing embryonic stem cells and controlled differentiation
US7145057B2 (en) 2002-02-01 2006-12-05 Origen Therapeutics, Inc. Chimeric bird from embryonic stem cells
US7153684B1 (en) 1992-10-08 2006-12-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US7169610B2 (en) 2002-01-25 2007-01-30 Genzyme Corporation Serum-free media for chondrocytes and methods of use thereof
WO2007116870A1 (fr) * 2006-04-03 2007-10-18 Effector Cell Institute, Inc. Procédé de préparation de cellules analogues aux hépatocytes matures
US7294508B2 (en) 2001-08-23 2007-11-13 Reliance Life Sciences Pvt. Ltd. Isolation of inner cell mass for the establishment of human embryonic stem cell (hESC) lines
WO2008100497A1 (fr) * 2007-02-12 2008-08-21 Anthrogenesis Corporation Hépatocytes et chondrocytes provenant de cellules souches placentaires adhérentes ; et populations de cellules enrichies avec des cellules souches placentaires cd34+, cd45-
WO2009013254A1 (fr) 2007-07-20 2009-01-29 Cellartis Ab Nouvelle population d'hépatocytes issus d'endoderme définitif (de-hep) provenant de cellules souches de blastocystes humains
WO2010049752A1 (fr) 2008-10-31 2010-05-06 Katholieke Universiteit Leuven Procédés optimisés pour la différenciation de cellules en cellules présentant des phénotypes d'hépatocytes et de cellules souches d'hépatocytes, cellules produites par ces procédés et procédés pour l'utilisation des cellules
WO2011158125A2 (fr) 2010-06-17 2011-12-22 Katholieke Universiteit Leuven Procédé de différenciation de cellules en cellules étoilées du foie et en cellules endothéliales sinusoïdales du foie, cellules produites par ces procédés, et procédés d'utilisation des cellules

Patent Citations (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2212108A (en) 1938-04-23 1940-08-20 Tidewater Associated Oil Compa Process of treating rotary mud
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US6436701B1 (en) 1988-09-21 2002-08-20 Babraham Institute Derivation of pluripotential embryonic cell lines from ungulate species
US7037721B1 (en) 1990-01-29 2006-05-02 Hy-Gene Biomedical, Inc. Protein-free defined media for the growth of normal human keratinocytes
US5397706A (en) 1991-11-06 1995-03-14 Correa; Paulo N. Serum-free basal and culture medium for hematopoietic and leukemia cells
US5656479A (en) 1992-05-15 1997-08-12 North Carolina State University Avian embryonic stem cells
US5453357A (en) 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5670372A (en) 1992-10-08 1997-09-23 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US7153684B1 (en) 1992-10-08 2006-12-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5766951A (en) 1992-11-12 1998-06-16 Quality Biological, Inc. Serum-free medium supporting growth and proliferation of normal bone marrow cells
US6037174A (en) 1993-08-23 2000-03-14 Nexell Therapeutics, Inc. Preparation of serum-free suspensions of human hematopoietic cells or precursor cells
US6432711B1 (en) 1993-11-03 2002-08-13 Diacrin, Inc. Embryonic stem cells capable of differentiating into desired cell lines
US6500668B2 (en) 1994-10-21 2002-12-31 Jacques Samarut Culture medium for avian embryonic cells
US5874301A (en) 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US6110739A (en) 1994-11-21 2000-08-29 National Jewish Medical And Research Center Method to produce novel embryonic cell populations
US5914268A (en) 1994-11-21 1999-06-22 National Jewish Center For Immunology & Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US6200806B1 (en) 1995-01-20 2001-03-13 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US7029913B2 (en) 1995-01-20 2006-04-18 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5908782A (en) 1995-06-05 1999-06-01 Osiris Therapeutics, Inc. Chemically defined medium for human mesenchymal stem cells
US6190910B1 (en) 1996-05-21 2001-02-20 The Institute Of Physical And Chemical Research Mouse embryonic stem cell lines
US6372210B2 (en) 1996-10-18 2002-04-16 Quality Biological, Inc. Method for repopulating human bone marrow comprising culturing CD34+ cells in a serum free medium
US6224860B1 (en) 1996-10-18 2001-05-01 Quality Biological, Inc. Method for repopulating human bone marrow comprising culturing CD34+ cells in a serum free medium
US6617161B2 (en) 1997-06-25 2003-09-09 The United States Of America As Represented By The Department Of Health And Human Services Serum-free cell growth medium
US6617159B1 (en) 1998-11-09 2003-09-09 Consorzio Per La Gestione Del Centro Di Biotechnologie Avanzate Serum free medium for chondrocyte cells
US7109032B2 (en) 1998-11-09 2006-09-19 Consorzio Per La Gestione Del Centro Di Biotecnologie Avanzate Serum-free medium for mesenchymal stem cells
US6875607B1 (en) 1998-11-09 2005-04-05 Es Cell International Pte Ltd Embryonic stem cells
US20050153442A1 (en) 1999-03-10 2005-07-14 Adam Katz Adipose-derived stem cells and lattices
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US7112437B2 (en) 2000-06-20 2006-09-26 Es Cell International Pte Ltd. Methods of culturing embryonic stem cells and controlled differentiation
US20020164794A1 (en) 2000-11-03 2002-11-07 Peter Wernet Human cord blood derived unrestricted somatic stem cells (USSC)
US7294508B2 (en) 2001-08-23 2007-11-13 Reliance Life Sciences Pvt. Ltd. Isolation of inner cell mass for the establishment of human embryonic stem cell (hESC) lines
US20030059414A1 (en) 2001-09-21 2003-03-27 Ho Tony W. Cell populations which co-express CD49c and CD90
US6703279B2 (en) 2002-01-04 2004-03-09 Promos Technologies, Inc. Semiconductor device having contact of Si-Ge combined with cobalt silicide
US7169610B2 (en) 2002-01-25 2007-01-30 Genzyme Corporation Serum-free media for chondrocytes and methods of use thereof
US7145057B2 (en) 2002-02-01 2006-12-05 Origen Therapeutics, Inc. Chimeric bird from embryonic stem cells
US20030181269A1 (en) 2002-03-20 2003-09-25 Sara Griffin Portable, non-slip training aid for sports
US20060147246A1 (en) 2002-09-16 2006-07-06 Richards John M Grip for hand held instruments
WO2007116870A1 (fr) * 2006-04-03 2007-10-18 Effector Cell Institute, Inc. Procédé de préparation de cellules analogues aux hépatocytes matures
WO2008100497A1 (fr) * 2007-02-12 2008-08-21 Anthrogenesis Corporation Hépatocytes et chondrocytes provenant de cellules souches placentaires adhérentes ; et populations de cellules enrichies avec des cellules souches placentaires cd34+, cd45-
WO2009013254A1 (fr) 2007-07-20 2009-01-29 Cellartis Ab Nouvelle population d'hépatocytes issus d'endoderme définitif (de-hep) provenant de cellules souches de blastocystes humains
WO2010049752A1 (fr) 2008-10-31 2010-05-06 Katholieke Universiteit Leuven Procédés optimisés pour la différenciation de cellules en cellules présentant des phénotypes d'hépatocytes et de cellules souches d'hépatocytes, cellules produites par ces procédés et procédés pour l'utilisation des cellules
WO2011158125A2 (fr) 2010-06-17 2011-12-22 Katholieke Universiteit Leuven Procédé de différenciation de cellules en cellules étoilées du foie et en cellules endothéliales sinusoïdales du foie, cellules produites par ces procédés, et procédés d'utilisation des cellules

Non-Patent Citations (80)

* Cited by examiner, † Cited by third party
Title
ALISON ET AL., HEPATOLOGY, vol. 29, 1998, pages 678 - 683
ATALA, A., J TISSUE REGEN MED, vol. 1, 2007, pages 83 - 96
BARTENSCHLAGER, R.; PIETSCHMANN, T., PROC NATL ACAD SCI USA, vol. 102, 2005, pages 9739 - 9740
BRAMBRINK ET AL., CELL STEM CELL, vol. 2, 2008, pages 151 - 159
BRONS ET AL., NATURE, vol. 448, 2007, pages 191 - 195
CHAMBERS; SMITH, ONCOGENE, vol. 23, 2004, pages 7150 - 7160
CHUA ET AL., BIOMATERIALS, vol. 26, 2005, pages 2537 - 2547
CIBELLI ET AL., SCIENCE, vol. 295, 2002, pages L819
CLARKE ET AL., SCIENCE, vol. 288, 2000, pages 1660 - 1663
COWAN ET AL., SCIENCE, vol. 309, 2005, pages 1369 - 1373
DELGRANGE, D. ET AL., J GEN VIROL, vol. 88, 2007, pages 2495 - 2503
DO; SCHOLER, STEM CELLS, vol. 22, 2004, pages 941 - 949
DROBINSKAYA ET AL., STEM CELLS, vol. 26, 2008, pages 2245 - 2256
DVIR-GINZBERG ET AL., FASEB J, vol. 22, pages 1440 - 1449
EGGAN ET AL., NATURE, vol. 428, 2004, pages 44 - 49
EXP HEMATOL, vol. 30, 2002, pages 896
FARQUHAR M J ET AL: "Primary hepatocytes as targets for hepatitis C virus replication.", JOURNAL OF VIRAL HEPATITIS DEC 2008, vol. 15, no. 12, December 2008 (2008-12-01), pages 849 - 854, XP009167590, ISSN: 1365-2893 *
GUAN ET AL., NATURE, vol. 440, 2006, pages 1199 - 1203
HANNA ET AL., CELL, vol. 133, 2008, pages 250 - 264
HOCHEDLINGER; JAENISCH, NATURE, vol. 441, 2006, pages 1061 - 1067
IVANONA ET AL., NATURE, vol. 442, 2006, pages 533 - 538
JAENISCH ET AL., CELL, vol. 132, 2008, pages 567 - 582
JAHAGIRDAR, B.N. ET AL., EXP HEMATOL, vol. 29, 2001, pages 543 - 56
JIANG ET AL., NATURE, vol. 418, 2002, pages 41 - 49
JIANG, Y. ET AL., EXP HEMATOL, 2002, pages 30896 - 904
JIANG, Y. ET AL., NATURE, vol. 418, 2002, pages 41
JIANG, Y. ET AL., NATURE, vol. 418, 2002, pages 41 - 9
KANATSU-SHINOHARA ET AL., CELL, vol. 119, 2004, pages 1001 - 1012
KAPTEIN SJ; DE BURGHGRAEVE T; FROEYEN M; PASTORINO B; ALEN MM ET AL.: "A derivate of the antibiotic Doxorubicin is a selective inhibitor of dengue and yellow Fever virus replication in vitro", ANTIMICROB AGENTS CHEMOTHER, vol. 54, 2010, pages 5269 - 5280
KIROUAC ET AL., CELL STEM CELL, vol. 3, 2008, pages 369 - 381
KUCIA, M. ET AL., J PHYSIOL PHARMACOL, vol. 57, no. 5, 2006, pages 5 - 18
LEMON, S.M.; MURPHY, P.C.; SHIELDS, P.A.; PING, L.-H.; FEINSTONE, S.M.; CROMEANS, T.; JANSEN, R.W.: "Antigenic and genetic variation in cytopathic hepatitis A virus variants arising during persistent infection: evidence for genetic recombination", J. VIROL., vol. 65, 1991, pages 2056 - 2065
MASUI ET AL., NAT CELL BIOL, vol. 9, 2007, pages 625 - 635
MATSUI ET AL., CELL, vol. 70, 1992, pages 841 - 847
MATSUMOTO ET AL., J BIOSCIENCE AND BIOENGINEERING, vol. 105, 2008, pages 350 - 354
MEULEMAN, P.; LEROUX-ROELS, G., ANTIVIRAL RES, vol. 80, 2008, pages 231 - 238
MITCHELL, K.E. ET AL., STEM CELLS, vol. 21, 2003, pages 50 - 60
MIYAZAWA ET AL., JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, vol. 22, 2007, pages 1959 - 1964
NAHMIAS, Y. ET AL., HEPATOLOGY, vol. 47, 2008, pages 1437 - 1445
NAKAGAWA ET AL., NAT BIOTECHNOL, vol. 26, 2008, pages 191 - 106
NARASIMHA ET AL., CURR BIOL, vol. 7, 1997, pages 881 - 884
OHASHI ET AL., NATURE MEDICINE, vol. 13, 2007, pages 880 - 885
OKITA ET AL., NATURE, vol. 448, 2007, pages 313 - 317
PAESHUYSE J ET AL., ANTIMICROB AGENTS CHEMOTHER, vol. 52, no. 9, 2008, pages 3433 - 3437
PHINNEY; PROCKOP, STEM CELLS, vol. 25, 2007, pages 2896 - 2902
PODEVIN P ET AL: "Production of Infectious Hepatitis C Virus in Primary Cultures of Human Adult Hepatocytes", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 139, no. 4, 1 October 2010 (2010-10-01), pages 1355 - 1364.e6, XP027443215, ISSN: 0016-5085, [retrieved on 20100701], DOI: 10.1053/J.GASTRO.2010.06.058 *
POTTEN, C. ET AL., TRANS R SOC LOND B BIOL SCI, vol. 353, 1998, pages 821 - 830
REED, L.J.; MUENCH, H.: "A simple method for estimating fifty per cent endpoints", AM. J. EPIDEMIOL., vol. 27, 1938, pages 193 - 197
REVAZOVA ET AL., CLONING STEM CELLS, vol. 9, 2007, pages 432 - 449
REYES, M.; C.M. VERFAILLIE, ANN N YACAD SCI, vol. 938, 2001, pages 231 - 233
ROELANDT P ET AL: "858 UNIVERSAL HEPATOCYTE DIFFERENTIATION PROTOCOL FOR MULTIPOTENT ADULT PROGENITOR CELLS, EMBRYONIC AND INDUCED PLURIPOTENT STEM CELLS", JOURNAL OF HEPATOLOGY, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 50, 1 April 2009 (2009-04-01), pages S313, XP026496471, ISSN: 0168-8278, [retrieved on 20090401], DOI: 10.1016/S0168-8278(09)60860-6 *
ROELANDT, P. ET AL., PLOS ONE, vol. 5, 2010, pages E12101
SANCHO-BRU P ET AL: "Directed differentiation of murine-induced pluripotent stem cells to functional hepatocyte-like cells", JOURNAL OF HEPATOLOGY, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 54, no. 1, 1 January 2011 (2011-01-01), pages 98 - 107, XP027542106, ISSN: 0168-8278, [retrieved on 20100906] *
SCIENCE, vol. 318, 2006, pages 1917 - 1920
SEANDEL ET AL., NATURE, vol. 449, 2007, pages 346 - 350
SILBERSTEIN, E.; XING, L.; VAN DE BEEK, W.; LU, J.; CHENG, H.; KAPLAN, G.G.: "Alteration of hepatitis A virus (HAV) particles by a soluble form of HAV cellular receptor 1 containing the immunoglobin- and mucin-like regions", J. VIROL., vol. 77, 2003, pages 8765 - 8774
SILVA ET AL., NATURE, vol. 441, 2006, pages 997 - 1001
SOLTER, D., NAT REV GENET, vol. 7, 2006, pages 319 - 327
TADA ET AL., CURR BIOL, vol. 11, 2001, pages 1553 - 1558
TAKAHASHI ET AL., CELL, vol. 126, 2006, pages 663 - 676
TAKAHASHI ET AL., CELL, vol. 131, 2007, pages 861 - 872
TAKAHASHI; YAMANAKA, CELL, vol. 126, 2006, pages 663 - 676
TESAR ET AL., NATURE, vol. 448, 2007, pages 196 - 199
THOMSON ET AL., SCIENCE, vol. 282, 1998, pages 1145 - 1147
TOMA ET AL., NAT CELL BIOL, vol. 3, 2001, pages 778 - 784
TURNER ET AL., J BIOMED MATER RES PART B: APPL BIOMATER, vol. 82B, 2007, pages 156 - 168
VAN DE VEN ET AL., EXP HEMATOL, vol. 35, 2007, pages 1753 - 1765
VERFAILLIE, C.M., TRENDS CELL BIOL, vol. 12, 2002, pages 502 - 8
WAKAYAMA ET AL., STEM CELLS, vol. 25, 2007, pages 986 - 993
WATT, F., TRANS R SOC LOND B BIOL SCI, vol. 353, 1997, pages 831
WERNIG ET AL., PNAS, vol. 105, 2008, pages 5856 - 5861
WERNING ET AL., NATURE, vol. 448, 2008, pages 318 - 324
WILMUT ET AL., NATURE, vol. 385, 1997, pages 810 - 813
YAMANAKA, S. ET AL., CELL STEM CELL, vol. 1, 2007, pages 39 - 49
YAMANAKA, S., CELL STEM CELL, vol. 1, 2007, pages 39 - 49
YING ET AL., NATURE, vol. 416, 2002, pages 545 - 548
YU ET AL., SCIENCE, vol. 318, 2007, pages 1917 - 1920
ZHONG, J. ET AL., J VIROL, vol. 80, 2006, pages 11082 - 11093
ZHONG, J. ET AL., PROC NATL ACAD SCI USA, vol. 102, 2005, pages 9294 - 9299
ZWAKA; THOMSON, DEVELOPMENT, vol. 132, 2005, pages 227 - 233

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016061298A1 (fr) * 2014-10-15 2016-04-21 Coyne Ip Holdings, Llc Procédés de conduite d'études stimulus-réponse avec des cellules souches pluripotentes induites dérivées de cellules ou de tissus périnataux
CN107208060A (zh) * 2015-01-07 2017-09-26 先锋生药开发有限公司 应用人脂肪衍生的干细胞增殖血清来源的丙肝病毒及其用途
EP3242932A4 (fr) * 2015-01-07 2018-05-30 Frontier Bio-Drug Development Limited Utilisation de cellules souches dérivées de tissu adipeux humain pour la propagation du virus de l'hépatite c dérivée du sérum et son utilisation
US10273461B2 (en) 2015-01-07 2019-04-30 Frontier Bio-Drug Development Limited Employing human adipose-derived stem cells to propagate serum-derived hepatitis C virus and use thereof
CN107208060B (zh) * 2015-01-07 2021-06-18 威世药业（如皋）有限公司 应用人脂肪衍生的干细胞增殖血清来源的丙肝病毒及其用途
CN107916248A (zh) * 2016-10-06 2018-04-17 尼希尔株式会社 来源于人类干细胞的肝细胞分化方法及肝细胞
CN106754653A (zh) * 2017-03-06 2017-05-31 广州润虹医药科技有限公司 iPS细胞分化成内胚层祖细胞的无血清诱导培养基及诱导方法
CN106754653B (zh) * 2017-03-06 2019-09-27 广州润虹医药科技股份有限公司 iPS细胞分化成内胚层祖细胞的无血清诱导培养基及诱导方法
US11274279B2 (en) 2020-03-11 2022-03-15 Bit Bio Limited Method of generating hepatic cells

Also Published As

Publication number Publication date
GB201119335D0 (en) 2011-12-21

Similar Documents

Publication Publication Date Title
US9931360B2 (en) Isolated liver stem cells
US10457914B2 (en) Optimized methods for differentiation of cells into cells with hepatocyte and hepatocyte progenitor phenotypes, cells produced by the methods, and methods for using the cells
US9777258B2 (en) Methods for differentiating cells into hepatic stellate cells and hepatic sinusoidal endothelial cells, cells produced by the method, and methods for using the cells
US20190194607A1 (en) Highly functional liver cells derived from pluripotent stem cells, method for producing same, and method for testing metabolism/toxicity of drug
CN105121632A (zh) 由多能干细胞生成肝细胞和胆管细胞的方法
US20190046584A1 (en) Improved preparations of adult liver progenitor cells
JP2008514214A (ja) ヒト胚盤胞由来幹細胞（ｈＢＳ）から肝細胞様細胞を発生させる方法
WO2013068557A1 (fr) Cellules souches pouvant être infectées par des virus
Hu et al. Direct induction of hepatocyte-like cells from immortalized human bone marrow mesenchymal stem cells by overexpression of HNF4α
Bi et al. Induced maturation of hepatic progenitor cells in vitro
WO2013183571A1 (fr) Procédé d'induction de la différenciation d'une cellule souche pluripotente artificielle en un hépatocyte
JP2018530354A (ja) ウイルス受容性多能性幹細胞（ｐｓｃ）由来肝細胞の生産
EP3384011B1 (fr) Procédés de différenciation de cellules en cellules stellaires hépatiques
Jahnavi et al. Lineage reprogramming of human adipose mesenchymal stem cells to immune modulatory i-Heps
Min et al. Selective enrichment of hepatocytes from mouse embryonic stem cells with a culture system containing cholestatic serum 1
Tsai et al. Efficient programming of human mesenchymal stem cell‐derived hepatocytes by epigenetic regulations
JP6232638B2 (ja) 肝前駆細胞増殖用培地
JP6265385B2 (ja) アミノ酸製剤による細胞増幅法
Hong et al. SARS-CoV-2 and Malayan pangolin coronavirus infect human endoderm, ectoderm and induced lung progenitor cells
JP6807095B2 (ja) 肝前駆細胞の製造方法
US20190127692A1 (en) Production Method For Hepatocyte Lineage Cells, Hepatocyte Lineage Cell Or Culture Product Obtained By The Production Method, And Hepatocyte Differentiation-Inducing Medium
Nitaramorn et al. Human liver organoids are susceptible to Plasmodium vivax infection
Richardson Leveraging Induced Pluripotent Stem Cell Derived Hepatocyte Like Cells to Understand Liver Biology

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12788166

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12788166

Country of ref document: EP

Kind code of ref document: A1